Navigation Links
Infolytx Presents NLP Framework Solution to Improve Patient Identification for Clinical Trials at AMIA 2018
Date:11/5/2018

Infolytx, an AI and machine learning company, was asked to present its Natural Language Processing or NLP-based Electronic Health Records (EHR) Information Extraction framework solution to improve patient identification for clinical trials at the 2018 American Medical Informatics Association (AMIA) Annual Symposium, as part of the National NLP Clinical Challenge (n2c2) co-sponsored by Harvard Medical School (HMS) Department of Biomedical Informatics and George Mason University (GMU) School of Engineering. During the day-long, collaborative n2c2 Shared Task and Workshop on Friday, November 3, Infolytx shared its unique NLP-based solution with industry and academic institutions from across the globe as part of the workshop goal to collectively help resolve ongoing challenges in using NLP to optimize clinical research processes.

Challenge organizers tasked participants with providing a solution to the question: “Can NLP systems use narrative medical records to identify which patients meet selection criteria for clinical trials?” Infolytx and other participants, including IBM Research, Kaiser Permanente, and Stanford University, were required to thoroughly evaluate more than 200 patient records and compare each patient to a list of 13 specific selection criteria to identify individuals eligible for clinical trial participation. Challenge participants needed to scrub patient records using their NLP solution to find individuals who met all 13 requirements, which included: the ability to make their own medical decisions, major diabetes-related complications, and advanced cardiovascular disease.

Infolytx’ data extraction framework enabled automated, scalable, and unbiased selection of patients who met all 13 selection criteria for clinical trials. In vetting more than 200 patient records, the company’s framework provided a micro F1 of 86%.

“To truly combat traditional trial inefficiencies, including time-consuming and costly patient recruitment efforts, the industry needs NLP and other AI solutions to extract valuable information from unstructured data like patient records,” said Infolytx Chief Technology Officer Dr. Zunaid Kazi. “In this case, we can use this data to target the appropriate patients for a study to help keep the clinical development process moving quickly and with quality—improving health outcomes. This is just one critical way domain expertise combined with tech-driven solutions can help the industry and ultimately, patients.”

NLP and Clinical Development Acceleration
Patient identification and recruitment are some of the biggest challenges to advancing treatment development and making much-needed therapies available to patents. With increasingly complex selection criteria due to regulatory requirements, medical researchers have to examine patient records, including extensive notes and narratives, to recruit patients—limiting them to patients who seek out trials themselves or via physician recommendations. NLP and other tech-driven solutions can help mine clinical data in EHRs for keywords and phrases to better support needs of selection criteria to improve patient identification processes for clinical trials.

“Analyzing data—structured or unstructured—is a key focus area for us, and the invitation by the n2c2 Challenge organizers to share our insights further demonstrates our team’s competence to support and accelerate the efficacy of a variety of NLP applications” noted Infolytx CEO Badrul Husain.

About the National NLP Clinical Challenge (n2c2)
Harvard Medical School (HMS) Department of Biomedical Informatics and George Mason University (GMU) Volgenau School of Engineering co-sponsored the 2018 National NLP Clinical Challenge to task participants with providing a solution to the question: “Can NLP systems use narrative medical records to identify which patients meet selection criteria for clinical trials?” The task required NLP systems to thoroughly evaluate patient records and compare each patient to a list of 13 specific selection criteria to identify target patients eligible for clinical trial participation. NLP systems that automatically assess which patients will meet complex criteria for studies can both reduce time and cost related to patient recruitment and help remove bias from trials.

Challenge co-chairs and AMIA NLP Processing Working Group Workshop organizers Özlem Uzuner, Associate Professor, information Sciences and Technology, at GMU, and Amber Stubbs, Assistant Professor, Math & Computational Sciences, at Simmons University, selected Infolytx along with four other participants—from the over 100 Challenge submissions—to orally present its unique NLP solution. Another 13 participants, including Stanford University School of Medicine (co-authors with Oracle and National Institutes of Health), Med Data Quest, and Kaiser Permanente, shared poster presentations at the 2018 AMIA annual symposium on November 2, 2018. For more information on the Challenge, visit the n2c2 page.

About Infolytx
Infolytx is an AI and machine learning company building solutions to help healthcare and other high-tech industries understand and monetize their data. Data that is disparate, structured or unstructured can be integrated, mined, analyzed, visualized, and presented by our expert data engineers and scientists.

Today’s competitive marketplace demands that savvy companies take advantage of every asset and tool at their disposal – Infolytx can help companies tap into their data sets to gain crucial insights. With our cutting-edge technologies and world-class methodologies, we provide companies with significant competitive advantage. For more information, please visit the Infolytx site.

Read the full story at https://www.prweb.com/releases/2018/11/prweb15892210.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
2. BioElectronics Presents FDA Reclassification Panel
3. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
4. NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
5. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
6. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
7. NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting
8. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
9. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the FedEx St. Jude Classic
10. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
11. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... Gwinnett Family Dental Care , located ... of complete dental care, including general and preventative care as well as restorative and ... team of extensively trained dentists, Dr. Kell Gallaher, Dr. Jon Klevansky, Dr. Jason Klevansky, ...
(Date:7/17/2019)... ... July 17, 2019 , ... Cognition Corporation , ... a new e-book on developing user needs for life science products. ... a small part of the compliance process and the guiding force for product ...
(Date:7/17/2019)... ... 16, 2019 , ... Steven C. Bilt, Chief Executive Officer of Smile Brands ... the dental industry during a panel discussion at Dykema’s 6th Annual Definitive Conference for ... Dallas Hotel in Dallas, Texas. , Bilt co-founded Smile Brands Inc. in 1998 and ...
Breaking Medicine Technology:
(Date:7/17/2019)... ... ... A new study led by researchers at the University of Pittsburgh and published ... the first time that New York’s sepsis protocols are directly responsible for the significant ... infection. It kills more than 275,000 Americans each year and leaves hundreds of thousands ...
(Date:7/17/2019)... ... July 16, 2019 , ... A medical home care program found that ... key to better care for seniors. While this may not sound surprising, a recent ... through its Brandman Research Institute (BRI) uncovered several surprising outcomes based on a simple ...
(Date:7/17/2019)... ... ... Dr. Jonathan Zaidan, MD, FACOG, President of Women’s Excellence discusses a new weight loss ... on Wednesday, July 17ths at 7pm. The show podcast will be available online ... the challenges that women face when it comes to weight loss and any health ...
(Date:7/13/2019)... ... July 13, 2019 , ... ZALO , the ... and innovative rechargeable vibrator and clitoral massager. To view the product and its accompanying ... newest and most advanced, personal massagers to people around the world,” said Mara Epstein, ...
(Date:7/13/2019)... ... July 12, 2019 , ... Ospitek Inc., a leading provider ... platform, Ospitek “View”. Ospitek has partnered with some of the country’s leading surgeons, ... solution made specifically for surgical centers, allowing them to directly engage with patients ...
Breaking Medicine News(10 mins):